Yes, it is possible to see only in black and white, though it is extremely rare. The condition is called achromatopsia, and people who have the complete form perceive the world entirely in shades of gray. Roughly 1 in 30,000 to 50,000 people worldwide are affected. It can be present from birth due to a genetic mutation, or it can develop later in life after specific types of brain damage.
Why Color Vision Fails
Normal color vision depends on three types of cone cells in the retina, each tuned to a different range of light wavelengths: red, green, and blue. Your brain blends the signals from all three cone types to produce the full spectrum of colors you see. In complete achromatopsia, none of the three cone types work. The cones are physically present in the retina, but they cannot properly respond to light because of defects in the signaling chain inside the cell. Four different genes have been identified so far that, when mutated, cause this breakdown.
With no functioning cones, vision relies entirely on rod cells. Rods are the photoreceptors designed for low-light situations, and they do not distinguish color. They only register brightness. So a person with complete achromatopsia effectively sees the world the way you might see a dimly lit room at night: in grayscale, with no color information at all.
Congenital vs. Acquired Achromatopsia
Most people with black-and-white vision were born with it. Congenital achromatopsia is inherited as a recessive trait, meaning both parents must carry the gene. Symptoms appear within the first few weeks of life, typically starting with involuntary back-and-forth eye movements (nystagmus) followed by obvious discomfort in bright light.
A much rarer path to black-and-white vision is brain damage. The brain processes color in a region of the visual cortex called the V4 complex, located in the lower back portion of the brain. A stroke or injury to this area can strip away color perception even though the eyes and retinas are completely healthy. In one documented case, a woman lost all color vision only after suffering two separate strokes to the occipital region on different occasions. This acquired form, called cerebral achromatopsia, can affect one or both eyes depending on which side of the brain is damaged.
It’s More Than Losing Color
People with complete congenital achromatopsia don’t just lose color. Because their vision depends entirely on rod cells, which were never designed to be the primary system in daylight, several other problems come along with it.
- Severe light sensitivity. Bright environments like a sunny parking lot or a fluorescent-lit office can be physically painful. Rod cells saturate quickly in bright light, causing glare and discomfort that most people never experience.
- Reduced sharpness. Visual acuity in complete achromatopsia is typically 20/200 or worse, which is the threshold for legal blindness in many countries. Incomplete forms may preserve acuity closer to 20/80.
- Nystagmus. The involuntary eye movements that begin in infancy are a hallmark feature. They tend to improve slightly with age but do not fully resolve.
- Central blind spot. Some individuals have a small scotoma (blind spot) in the center of their visual field, which can make tasks like reading more difficult.
Visual acuity tends to remain stable over a person’s lifetime. It does not progressively worsen, and both the nystagmus and light sensitivity may ease somewhat with age.
Incomplete Achromatopsia and Blue Cone Monochromatism
Not everyone with severely impaired color vision sees in pure black and white. Incomplete achromatopsia leaves some residual cone function, allowing limited color discrimination. People with this form have better visual acuity (sometimes reaching 20/80) and often do not experience the crushing light sensitivity of the complete form.
A related condition called blue cone monochromatism affects only males, since it is X-linked. In this case, the red and green cone systems are nonfunctional, but the blue cones still work. The result is a very limited palette rather than pure grayscale. Someone with blue cone monochromatism can detect some blue-yellow differences but cannot distinguish reds from greens, and their overall color world is drastically narrowed compared to typical vision.
How It’s Diagnosed
The familiar dot-pattern test (where you try to read a number hidden inside a circle of colored dots) can flag color vision problems, but it cannot distinguish between common red-green color blindness and total color blindness. Diagnosing achromatopsia requires more specialized testing. An electroretinogram, which measures the electrical response of the retina to flashes of light, can confirm whether cone cells are functioning. Genetic testing can then pinpoint the specific mutation responsible, which matters both for confirming the diagnosis and for determining eligibility for potential treatments.
Managing Daily Life
The biggest practical challenge for most people with achromatopsia is light, not the absence of color. Deep red-tinted lenses are commonly used to reduce the amount of light reaching the retina, which prevents rod saturation and relieves discomfort. These tinted lenses do more than just cut glare. They have been shown to improve visual acuity, shrink central blind spots, and widen the usable peripheral visual field. Both tinted glasses and tinted contact lenses are used, depending on personal preference and the severity of symptoms.
Driving is a significant barrier. Most U.S. states require a minimum visual acuity of 20/40, which is well beyond what complete achromatopsia allows. Massachusetts also explicitly requires drivers to distinguish red, green, and amber. In practice, most people with complete achromatopsia do not qualify for a standard driver’s license.
Many people with achromatopsia develop strategies for navigating a color-coded world. Traffic lights, for instance, can be read by position (top, middle, bottom) rather than color. Clothing can be organized by labels or texture. Digital accessibility features on phones and computers, including high-contrast modes and screen dimming, help reduce strain during screen time.
Gene Therapy Efforts
Because congenital achromatopsia traces back to specific, well-identified gene mutations, it has been a target for gene therapy research. Clinical trials have tested delivering corrected copies of the faulty genes directly into the retina using a viral carrier. Early-phase trials targeting the two most common mutations (in the CNGA3 and CNGB3 genes) have been conducted, and at least one long-term follow-up study posted results in June 2025. That particular trial was terminated due to a strategic business decision, not safety concerns. Gene therapy for achromatopsia remains experimental, and no approved treatment currently exists that restores cone function in humans.